Option chain shows key data for IO Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for IO Biotech.

IO Biotech (NASDAQ:IOBT) Stock, Option Chain

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGFY

EFSH

GLMD

HCTI

IOBT

ISPC

LUNR

MKDW

NEGG

OMEX

PRTG

SMSI

TNON

VEEA

VVPR

WATT

WBUY

WINT

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

ADAG

ATPC

DRMA

EGIO

ENTO

ITOS

LDTC

NCNA

PPBT

PTIX

SQFT

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Crude-oil-4-logo

Earnings

Equities

Eurozone

Commodities

Intraday Update

CNFR

RXRX

SGRP

SIFY

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher

IO Biotech Inc

Buybacks

CRH Entered Arrangement With TD Securities To Repurchase Ordinary Shares On CRH's Behalf For Aggregate Maximum Consideration Up To $300M

WIIM

Laird Superfood shares are trading lower after the company reported worse-than-expected Q4 sales results.

Matterport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 50 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $43.82 million which beat the analyst consensus estimate of $42.85 million by 2.26 percent. This is a 10.81 percent increase over sales of $39.55 million the same period last year.

Earnings Beats

Earnings Misses

MTTR

Matterport Q4 Adj $(0.02) Misses $(0.01) Estimate, Sales $43.82M Beat $42.85M Estimate

Stock Split

CLEU

China Liberal Education Holdings Announces The Company Plans To Effect A Share Consolidation Of Eighty Ordinary Shares With Par Value Of $0.225 Per Share Into One Ordinary Share With Par Value Of $18.0

BLMZ

BloomZ shares are trading higher after the company announced it regained compliance with Nasdaq.

IONQ

IonQ Announces At-the-Market Equity Offering Program For Up To $500M

Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) has outperformed the market over the past 20 years by 3.08% on an annualized basis producing an average annual return of 11.29%. Currently, Martin Marietta Materials has a market capitalization of $29.95 billion. 
Buying $100 In MLM: If an investor had bought $100 of MLM stock 20 years ago, it would be worth $850.44 today based on a price of $491.13 for MLM at the time of writing.
<h3>Martin Marietta Materials's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740606400_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Martin Marietta Materials 20 Years Ago Would Be Worth This Much Today

Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) sees Q1 sales of $140.000 million-$144.000 million vs $141.49 million analyst estimate.

Guidance

MGNI

Magnite Sees Q1 Sales $140.000M-$144.000M vs $141.49M Est

Magnite shares are trading lower following a Q4 adjusted EPS miss.

CPRX

Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Snowflake, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) reported its fourth-quarter results after Wednesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/02/b43989534/snowflake-reports-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2025">figures from the report.&nbsp;</a>
The Details:&nbsp;Snowflake reported quarterly earnings of 30 cents per share, which beat the analyst consensus estimate of 17 cents. Quarterly revenue of $986.77 million beat the analyst consensus estimate of $955.93 million and is an increase over revenue of $774.7 million from the same period last year.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43949800/tesla-competes-against-chinese-rivals-with-one-hand-tied-behind-its-back-analyst"> Tesla Competes Against Chinese Rivals &#8216;With One Hand Tied Behind Its Back&#8217;: Analyst</a>
For the fourth quarter, Snowflake reported:
<ul>
<li>Product revenue of $943.3 million, representing 28% year-over-year growth</li>
<li>Net revenue retention rate of 126%</li>
<li>580 customers with trailing 12-month product revenue greater than $1 million</li>
<li>745 Forbes Global 2000 customers</li>
<li>Remaining performance obligations of $6.9 billion, representing 33% year-over-year growth</li>
</ul>
Snowflake <a href="https://www.benzinga.com/pressreleases/25/02/b43989493/snowflake-securely-integrates-microsoft-azure-openai-service-to-provide-access-to-the-latest-opena">also announced </a>an expanded partnership with Microsoft Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) that integrates Microsoft OpenAI service, providing access to OpenAI&#8217;s models.
&#8220;We delivered another strong quarter, with product revenue of $943 million, up a strong 28% year-over-year, and remaining performance obligations totaling $6.9 billion,&#8221; said Sridhar Ramaswamy, CEO of Snowflake. 
&#8220;Today, Snowflake is the most consequential data and AI company in the world. More than 11,000 customers are already betting their business on our easy-to-use, efficient, and trusted platform. We see tremendous opportunities ahead to support our customers throughout their end-to-end data lifecycle, and we are laser-focused on delivering on this vision,&#8221; Ramaswamy added. 
Outlook:&nbsp;Snowflake sees first-quarter revenue in a range of $955 million to $960 million, versus the $1 billion estimate. The company sees fiscal 2026 revenue of $4.28 billion, versus the $4.41 billion estimate. 
SNOW Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Snowflake shares are up 9.27% after-hours at $181.60 on Wednesday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains &#8216;Largely Stuck&#8217;&nbsp;</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Tech

MSFT

SNOW

Snowflake Beats Q4 Estimates, Expands Microsoft Partnership To Include OpenAI Models

Western Midstream Announces Pathfinder Pipeline Expansion

Dividends

Xcel Energy Increases Quarterly Dividend From $0.5475 To $0.57

FirstEnergy shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results and issued FY25 core EPS guidance below estimates.

BloomZ Regains Compliance With Nasdaq

Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) affirms FY2025 sales outlook from $51.60 million-$55.00 million to $51.60 million-$55.00 million vs $52.49 million estimate.

Laird Superfood Affirms FY2025 Sales Guidance of $51.60M-$55.00M vs $52.49M Est

PSTG

Pure Storage shares are trading lower after the company issued FY26 revenue guidance below estimates.

Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) sees FY2025 sales of $735.000 million-$785.000 million vs $766.56 million analyst estimate.

Montrose Environmental Gr Sees FY2025 Sales $735.000M-$785.000M vs $766.56M Est

Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.39 by 12.82 percent. This is a 17.24 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $194.00 million which beat the analyst consensus estimate of $184.26 million by 5.29 percent. This is a 3.78 percent increase over sales of $186.93 million the same period last year.

Magnite Q4 Adj $0.34 Misses $0.39 Estimate, Sales $194.00M Beat $184.26M Estimate

Management

IonQ Appoints Niccolo de Masi As President And CEO

Health Care

Press Releases

General

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Financing

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Comments

IO Biotech

IO Biotech (IOBT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga